(1) Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005 Dec 1;106(12):3699-3709.
(2) Hill A. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. Blood 2006;108a:Abstract 985.
(3) Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 1954 Aug 20;120(3112):279-285.
(4) Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 1983 Sep;80(17):5430-5434.
(5) Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989 Jul;84(1):7-17.
(6) Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A 1983 Aug;80(16):5066-5070.
(7) Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993 May 21;73(4):703-711.
(8) de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008 Oct 15;112(8):3099-3106.
(9) Hillmen P et al ; High incidence of progression to chronic renal insufficiency in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007, 110, 3678
(10) Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013 Jun 20;121(25):4985-96; quiz 5105.
(11) Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010 Jul;78(4):211-230.
(12) Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004 Feb 5;350(6):552-559.
(13) Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007 Dec 1;110(12):4123-4128.
(14) Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008 Feb 15;111(4):1840-1847.
(15) Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010 May;149(3):446-450.
(16) Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, et al. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med 2015 Sep 10;373(11):1032-1039.
Kimmo Porkka, Riitta Lassila, Kari Remes, Eeva-Riitta Savolainen (toim.), Veritaudit 4., uudistettu painos, Duodecim 2015
Canadian immunization guide http://healthycanadians.gc.ca/publications/healthy-living-vie-saine/4-ca...
ACIP CDC https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6441a3.htm
Terveyden ja hyvinvoinnin laitos https://www.thl.fi/fi/web/rokottaminen
Suomen PNH-ryhmä
Elina Armstrong (pj), Hanna Jarva, Eva-Stina Korkama (siht), Minna Lehto, Seppo Meri, Tarja-Terttu Pelliniemi, Eira Poikonen, Jonna Salonen, Marjatta Sinisalo sekä Marjaana Säily
Kiitämme osastonylilääkäri, dosentti Veli-Jukka Anttilaa HUSin infektiosairauksien klinikasta arvokkaista kommenteista ja konsultaatioavusta.